Navigation Links
QLT announces third quarter results for 2008
Date:10/28/2008

VANCOUVER, Oct. 28 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today reported financial results for the third quarter ended September 30, 2008. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.

"This has been a very productive quarter for QLT," said Bob Butchofsky, President and Chief Executive Officer of QLT. "The Company is in a much stronger position today than it was at the beginning of the year. The successful divestment of three assets provided us with enough capital to redeem our convertible debt and it leaves us in a position of strength with $155.9 million in unrestricted cash. Also, our royalty revenue from Visudyne(R) and Eligard(R) continue to be significant to the Company and provide additional funding for our internal development programs, including our proprietary punctal plug drug elution technology trials. As we announced separately this morning, the data from our Phase 2 CORE trial showed a meaningful reduction in intra-ocular pressure, suggesting that we are making progress in advancing this platform technology."

In a separate matter, QLT's worldwide Visudyne licensee, Novartis, recently announced a restructuring of its U.S. commercial organization. As part of the restructuring, Novartis will no longer have a dedicated Ophthalmic sales force, however it will continue to support Visudyne in the U.S. with indirect sales methods. In the near term, we expect profitability to increase as a result of reduced selling and administrative expenses.

2008 Q3 FINANCIAL RESULTS

Worldwide Product Sales

As previously announced, global Visudyne sales for the third quarter were $34.1 million, a decrease of 30.1% from sales in the third quarter of 2007. Sales in the U.S. were $9.1 million, down 2.9% from the prior-year third quarter, while sales outside the U.S. were $24.9 million, down 36.6% from the prior year. The drop in Visudyne sales was primarily due to the approval and reimbursement in Europe of alternative therapeutics for age-related macular degeneration. We now believe that Visudyne sales for the year will be at the low end of our guidance range of $145 million to $160 million.

Worldwide Eligard sales in the third quarter were $54.7 million, an increase of 18.3% over the third quarter of 2007. U.S. sales of $16.9 million were down 9.5% from last year's third quarter, while sales outside the U.S. increased 37.2% to $37.8 million.

QLT Revenues

For the third quarter, total revenue of $10.9 million was down 25.6% from the third quarter of 2007 due primarily to the drop in worldwide Visudyne product sales, which more than offset the improvement in Visudyne profitability. QLT's share of profit from Visudyne sales in the third quarter was 22.6%, up from 18.8% a year ago, as spending to support the product fell more than 40% from the prior-year quarter. All royalty and product revenues derived from Eligard product sales are now included in Income from discontinued operations, net of income taxes.

QLT Expenses

For the third quarter of 2008, expenditures for research and development (R&D) were $6.9 million compared to $9.1 million in the same period of 2007. The decrease occurred as increased spending on the punctal plug program was more than offset by declines related to preclinical research and lemuteporfin. Selling, general and administrative (SG&A) expense was $4.4 million, down from $6.0 million in the third quarter of 2007, primarily due to savings realized from our restructuring.

Gains on Asset Divestments

QLT reported gains on the three divestments that occurred during the third quarter. The gain on the sale of the building and land of $21.3 million was included as a separate line item within continuing operations. The combined pre-tax gains on the divestures of Aczone(R) and Atrigel(R) of $134.3 million were reported as part of income from discontinued operations.

Operating Income/Loss

Operating income for the third quarter was $17.0 million, but excluding the gain on the sale of building and land we had an operating loss of $4.2 million. This compared favorably to an operating loss of $6.5 million in the prior-year quarter as a result of lower operating expenses, which more than offset the drop in contribution from Visudyne.

Income from Discontinued Operations, Net of Income Taxes

Income from discontinued operations, net of income taxes, was $134.8 million for the third quarter compared to income of $2.2 million in the third quarter last year. The increase was driven by gains realized on the divestment of Aczone and Atrigel during the quarter.

Earnings Per Share (EPS)/Loss Per Share

QLT reported EPS of $1.97 in the third quarter of 2008 compared to EPS of $0.00 in the prior-year quarter. The improvement was primarily the result of gains recorded related to asset divestments during the quarter.

In the third quarter, non-GAAP EPS was $0.05, as the gains on asset divestments, restructuring charge, stock compensation, accrued cost of sales re: MEEI and other items were backed out of GAAP EPS. The full reconciliation of GAAP to non-GAAP EPS for the third quarter and nine months is provided in Exhibits 1 and 2, attached.

Cash and Short-Term Investments

The Company's consolidated cash balance at September 30, 2008 consisted of $155.9 million of cash and cash equivalents and $124.0 million of restricted cash. The restricted cash balance related to the bond posted to stay the execution of the July 17, 2007 judgment, pending appeal, in the MEEI litigation. During the quarter, the Company redeemed all of the $172.5 million of convertible notes that it issued in August 2003. The reported September 30, 2008 cash balance reflects collection of the net proceeds for the three asset divestments, repayment of the convertible notes, as well as a $16.5 million cash installment paid for income taxes that is expected to be adequate to cover all tax liabilities resulting from the three divestments during the quarter.

RECENT COMPANY HIGHLIGHTS

* Released data from the Phase 2 CORE trial that is a study using QLT's punctal plug delivery technology in combination with Xalatan(R) and a conventional plug in patients with glaucoma or ocular hypertension.

* Completed the previously disclosed agreement to sell the land and building comprising the Company's corporate headquarters and the adjacent undeveloped parcel of land in Vancouver, British Columbia for Cdn$65.5 million to Discovery Parks Holdings Ltd. ("Discovery Parks"), in its capacity as trustee of Discovery Parks Trust and Discovery Parks Trust 2. In conjunction with the sale, QLT entered into a five-year lease with Discovery Parks for approximately thirty percent of the facility and will provide two-year 6.5% interest-only second mortgage vendor financing in the amount of Cdn$12 million.

* Entered into an exclusive license agreement with Reckitt Benckiser Pharmaceuticals Inc. for Atrigel, a sustained-release drug delivery technology, except for certain rights being retained by QLT USA and its prior licensees. Under the terms of the license agreement and related asset purchase agreement, QLT USA received an aggregate upfront payment of US$25 million and may receive potential milestone payments of up to US$5 million based on the successful development of two Atrigel-formulated products. As part of the transaction, Reckitt acquired 18 employees from QLT USA and took over most of its corporate facility located in Fort Collins, Colorado.

* Initiated a Phase I safety study in healthy adults of QLT091001, an orally administered synthetic retinoid replacement therapy for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle. The drug is being developed under a Co-Development agreement with Retinagenix LLC for the potential treatment of Leber's Congenital Amaurosis (LCA), an inherited progressive retinal degenerative disease that leads to retinal dysfunction and visual impairment beginning at birth. Phase I data is expected to be reported in the first half of 2009.

* Completed the redemption of $172.5 million of convertible notes.

UPCOMING EVENTS

On November 10, 2008, as part of the FP04 Glaucoma Original Paper Session, Dr. Rick Lewis, the principal investigator and co-authors Carolina Mendoza-Perez MD and Gustavo Velasco Gallegos will be presenting the previously announced results of QLT's punctal plug delivery proof-of-concept study at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, GA.

PA034 Enhancing Patient Compliance Using a Punctal Plug Delivery

System for Reduction of Elevated IOP in the Management of Glaucoma

Date and Time: Monday Nov 10, 08:42 AM - 08:50 AM

Location: Georgia World Congress Center,

Room: A411

On November 12, 2008 Bob Butchofsky, CEO, will be giving a corporate presentation at the Rodman & Renshaw Annual Global Investment Conference in New York, NY.

The Company expects to present six-month results from its RADICAL trial before year-end. The RADICAL trial is a Phase II, multicenter, randomized, single-masked study comparing reduced-fluence Visudyne-Lucentis combination therapies and Lucentis monotherapy in subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Conference call information

QLT Inc. will hold an investor conference call to discuss third quarter 2008 results on Tuesday, October 28, 2008 at 8:30 a.m. ET (5:30 a.m. PT). The call will be broadcast live via the Internet at http://www.qltinc.com. To participate on the call, please dial 1-800-319-4610 (North America) or 604-638-5340 (International) before 8:30 a.m. ET. A replay of the call will be available via the Internet and also via telephone at 1-800-319-6413 (North America) or 604-638-9010 (International), access code 7157, followed by the number sign.

About QLT

QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the field of ophthalmology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to create products such as Visudyne(R) and Eligard(R) and future product opportunities. For more information, visit our web site at http://www.qltinc.com.

QLT Inc.-Financial Highlights

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In accordance with United States generally accepted accounting

principles)

(In thousands of United Three months ended Nine months ended

States dollars, except September 30, September 30,

per share information) 2008 2007 2008 2007

-------------------------------------------------------------------------

(Unaudited)

Revenues

Net product revenue $ 10,868 $ 14,606 $ 36,462 $ 54,170

Costs and expenses

Cost of sales 1,969 2,805 7,331 9,432

Accrued cost of sales

re: MEEI(1) 1,020 1,461 3,332 1,461

Research and development 6,887 9,081 23,049 26,236

Selling, general and

administrative 4,422 5,989 15,519 15,980

Depreciation 464 1,334 2,566 3,910

Litigation - 265 864 110,162

Gain on sale of long-

lived assets (21,289) - (21,289) -

Restructuring charge 349 174 9,439 668

-------------------------------------------------------------------------

(6,178) 21,109 40,811 167,849

-------------------------------------------------------------------------

Operating income (loss) 17,046 (6,503) (4,349) (113,679)

Investment and other

(expense) income

Net foreign exchange losses (296) (863) (58) (1,285)

Interest income 1,853 3,818 5,789 11,163

Interest expense (2,743) (2,735) (8,811) (5,965)

Other 26 3,165 288 4,429

-------------------------------------------------------------------------

(1,160) 3,385 (2,792) 8,342

-------------------------------------------------------------------------

Income (loss) from continuing

operations before income

taxes 15,886 (3,118) (7,141) (105,337)

(Provision) recovery of

income taxes (3,749) 1,316 (144) 36,233

-------------------------------------------------------------------------

Income (loss) from continuing

operations 12,137 (1,802) (7,285) (69,104)

-------------------------------------------------------------------------

Income from discontinued

operations, net of income

taxes 134,789 2,153 136,302 5,653

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Net Income (loss) $ 146,926 $ 351 $ 129,017 $ (63,451)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Basic net income (loss) per

common share

Continuing operations $ 0.16 $ (0.02) $ (0.10) $ (0.92)

Discontinued operations 1.81 0.03 1.83 0.08

-------------------------------------------------------------------------

Net income (loss) $ 1.97 $ 0.00 $ 1.73 $ (0.85)

Diluted net income (loss) per

common share

Continuing operations $ 0.16 $ (0.02) $ (0.10) $ (0.92)

Discontinued operations 1.81 0.03 1.83 0.08

-------------------------------------------------------------------------

Net income (loss) $ 1.97 $ 0.00 $ 1.73 $ (0.85)

Weighted average number of

common shares outstanding

(in thousands)

Basic 74,620 74,618 74,620 75,003

Diluted 74,620 74,624 74,620 75,003

-------------------------------------------------------------------------

(1) Amount accrued on Visudyne sales since June 30, 2007 pursuant to

and pending outcome of appeal of the judgment rendered in the MEEI

litigation.

QLT Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In accordance with United States generally accepted accounting

principles)

September 30, December 31,

(In thousands of United States dollars) 2008 2007

-------------------------------------------------------------------------

(Unaudited)

ASSETS

Current assets

Cash and cash equivalents $ 155,945 $ 126,731

Restricted cash 123,964 123,495

Accounts receivable 29,834 25,257

Income taxes receivable 64,523 48,421

Inventories 12,433 18,511

Current portion of deferred income tax assets 11,843 19,392

Other 8,467 11,930

-------------------------------------------------------------------------

407,009 373,737

-------------------------------------------------------------------------

Property, plant and equipment 3,943 11,643

Assets held for sale 48 41,107

Deferred income tax assets 31,375 7,041

Goodwill 23,145 94,903

Mortgage receivable 11,276 -

Long-term inventories and other assets 23,640 20,556

-------------------------------------------------------------------------

$ 500,436 $ 548,987

-------------------------------------------------------------------------

-------------------------------------------------------------------------

LIABILITIES

Current liabilities

Accounts payable $ 9,442 $ 8,486

Accrued restructuring charge 800 153

Accrued liabilities 131,509 123,294

Convertible debt - 172,500

Current portion of deferred revenue 7,459 8,431

Current portion of deferred income tax

liabilities - 11,291

-------------------------------------------------------------------------

149,210 324,155

Uncertain tax position liabilities 2,122 2,070

Deferred revenue 1,837 2,939

-------------------------------------------------------------------------

153,169 329,164

-------------------------------------------------------------------------

SHAREHOLDERS' EQUITY

Common shares 702,221 702,221

Additional paid in capital 122,676 119,779

Accumulated deficit (585,438) (714,455)

Accumulated other comprehensive income 107,808 112,278

-------------------------------------------------------------------------

347,267 219,823

-------------------------------------------------------------------------

$ 500,436 $ 548,987

-------------------------------------------------------------------------

-------------------------------------------------------------------------

As at September 30, 2008, there were 74,620,328 issued and outstanding

common shares and 6,064,688 outstanding stock options.

QLT Inc.

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

----------------------------------------------

2008 Third Quarter Reconciliation of GAAP Earnings

to Adjusted Non-GAAP Earnings Exhibit 1

-------------------------------------------------------------------------

Three months

Three months ended

(In millions of United ended September 30,

States dollars, except September 30, 2008

per share information) 2008 GAAP Adjustments Non-GAAP(1)

-------------------------------------------------------------------------

(Unaudited)

Revenues

Net product revenue $ 10.9 $ - $ 10.9

Cost and expenses

Cost of sales (2.0) 0.0 (a) (2.0)

Accrued cost of sales re: MEEI (1.0) 1.0 (b) -

Research and development (6.9) 0.2 (a) (6.7)

Selling, general and administrative (4.4) 0.5 (a) (3.9)

Depreciation (0.5) - (0.5)

Litigation - - -

Gain on sale of long-lived assets 21.3 (21.3)(c) -

Restructuring (0.3) 0.3 (d) -

-------------------------------------------------------------------------

6.2 (19.2) (13.0)

-------------------------------------------------------------------------

Operating income (loss) 17.0 (19.2) (2.2)

Investment and other (expense)

income

Net foreign exchange losses (0.3) - (0.3)

Interest income 1.9 - 1.9

Interest expense (2.7) 1.5 (b) (1.2)

Other 0.0 - 0.0

-------------------------------------------------------------------------

(1.2) 1.5 0.4

-------------------------------------------------------------------------

Income (loss) from continuing

operations before income taxes 15.9 (17.7) (1.8)

Provision for income taxes (3.7) 3.7 (e) (0.0)

-------------------------------------------------------------------------

Income (loss) from continuing

operations 12.1 (14.0) (1.8)

-------------------------------------------------------------------------

Income from discontinued

operations, net of income taxes 134.8 (129.3)(a)(d) 5.4

(f)(g)

-------------------------------------------------------------------------

Net income $ 146.9 $(143.3) $ 3.6

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Basic net income per common

share:

Continuing operations $ 0.16 $ (0.02)

Discontinued operations 1.81 0.07

-------------------------------------------------------------------------

Net income $ 1.97 $ 0.05

Diluted net income per common

share:

Continuing operations $ 0.16 $ (0.02)

Discontinued operations 1.81 0.07

-------------------------------------------------------------------------

Net income $ 1.97 $ 0.05

Weighted average number of common

shares outstanding (in millions)

Basic 74.6 74.6

Diluted 74.6 74.6

Adjustments:

------------

(a) Remove stock based compensation.

(b) Remove accrued cost of sales re: MEEI and related interest expense.

(c) Remove gain on sale of long-lived assets.

(d) Remove restructuring charge.

(e) Remove income tax impact of the above adjustments.

(f) Remove gain on sale of assets, net of tax.

(g) Remove recognition of tax asset related to reversal of valuation

allowance.

(1) The adjusted non-GAAP financial measures have no standardized meaning

under GAAP and are not comparable between companies. Management

believes that the adjusted non-GAAP financial measures are useful for

the purpose of financial analysis. Management uses these measures

internally to evaluate the Company's operating performance before

items that are considered by management to be outside of the

Company's core operating results.

QLT Inc.

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

----------------------------------------------

2008 Third Quarter Reconciliation of GAAP Earnings

to Adjusted Non-GAAP Earnings Exhibit 2

-------------------------------------------------------------------------

Nine months

Nine months ended

(In millions of United ended September 30,

States dollars, except September 30, 2008

per share information) 2008 GAAP Adjustments Non-GAAP(1)

-------------------------------------------------------------------------

(Unaudited)

Revenues

Net product revenue $ 36.5 $ (0.4)(a) $ 36.0

Cost and expenses

Cost of sales (7.3) 0.9 (a)(b) (6.4)

Accrued cost of sales re: MEEI (3.3) 3.3 (c) -

Research and development (23.0) 0.8 (b) (22.2)

Selling, general and

administrative (15.5) 1.3 (b) (14.2)

Depreciation (2.6) 0.2 (d) (2.4)

Litigation (0.9) 0.9 (e) -

Gain on sale of long-lived assets 21.3 (21.3)(f) -

Restructuring (9.4) 9.4 (g) -

-------------------------------------------------------------------------

(40.8) (4.5) (45.3)

-------------------------------------------------------------------------

Operating loss (4.3) (4.9) (9.2)

Investment and other (expense)

income

Net foreign exchange gains (0.1) - (0.1)

Interest income 5.8 - 5.8

Interest expense (8.8) 4.3 (c) (4.5)

Other 0.3 - 0.3

-------------------------------------------------------------------------

(2.8) 4.3 1.5

-------------------------------------------------------------------------

Loss from continuing operations

before income taxes (7.1) (0.6) (7.7)

Provision for income taxes (0.1) (1.1)(h) (1.3)

-------------------------------------------------------------------------

Loss from continuing operations (7.3) (1.7) (9.0)

-------------------------------------------------------------------------

Income from discontinued operations,

net of income taxes 136.3 (125.1)(a)(b) 11.2

(g)(i)

(j)

-------------------------------------------------------------------------

Net income $ 129.0 $(126.8) $ 2.2

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Basic net income per common share:

Continuing operations $ (0.10) $ (0.12)

Discontinued operations 1.83 0.15

-------------------------------------------------------------------------

Net income $ 1.73 $ 0.03

Diluted net income per common

share:

Continuing operations $ (0.10) $ (0.12)

Discontinued operations 1.83 0.15

-------------------------------------------------------------------------

Net income $ 1.73 $ 0.03

Weighted average number of common

shares outstanding (in millions)

Basic 74.6 74.6

Diluted 74.6 74.6

Adjustments:

------------

(a) Remove inventory write-down.

(b) Remove stock based compensation.

(c) Remove accrued cost of sales re: MEEI and related interest expense.

(d) Remove impairment of fixed assets.

(e) Remove litigation expense.

(f) Remove gain on sale of long-lived assets.

(g) Remove restructuring charge.

(h) Remove income tax impact of the above adjustments.

(i) Remove gain on sale of assets, net of tax.

(j) Remove recognition of tax asset related to reversal of valuation

allowance.

(1) The adjusted non-GAAP financial measures have no standardized meaning

under GAAP and are not comparable between companies. Management

believes that the adjusted non-GAAP financial measures are useful for

the purpose of financial analysis. Management uses these measures

internally to evaluate the Company's operating performance before

items that are considered by management to be outside of the

Company's core operating results.

QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc.

Atrigel is a registered trademark of QLT USA, Inc.

Visudyne is a registered trademark of Novartis AG.

Eligard is a registered trademark of Sanofi-aventis.

Aczone is a registered trademark of Allergan Sales, LLC.

QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."

A full explanation of how QLT determines and recognizes revenue resulting from Visudyne sales is contained in the financial statements contained in the periodic reports on Forms 10-Q and 10-K, under the heading "Significant Accounting Policies - Revenue Recognition." Visudyne sales are product sales by Novartis under its agreement with QLT.

Certain statements in this press release constitute "forward looking statements" of QLT within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute "forward looking information" within the meaning of applicable Canadian securities laws. Forward looking statements include, but are not limited to: our plans to divest certain of our assets; our expectations for timing to receive data from our CORE study and our Visudyne RADICAL study; our expectation in the near term of increased profitability from Visudyne sales as a result of reduced selling and administration expenses; and statements which contain language such as: "assuming," "prospects," "future," "projects," "believes," "expects" and "outlook." Forward-looking statements are predictions only which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed in such statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: the Company's future operating results are uncertain and likely to fluctuate; our ability to successfully complete the sale of one or more of our assets or operations at an acceptable price and the time period necessary to complete such sales are uncertain; uncertainties relating to the timing and results of the clinical development and commercialization of our products and technologies (including Visudyne and our punctal plug technology) and the associated costs of these programs; the timing, expense and uncertainty associated with the regulatory approval process for products; uncertainties regarding the impact of competitive products and pricing; risks and uncertainties associated with the safety and effectiveness of our technology; risks and uncertainties related to the scope, validity, and enforceability of our intellectual property rights and the impact of patents and other intellectual property of third parties; and general economic conditions and other factors described in detail in QLT's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward looking statements are based on the current expectations of QLT and QLT does not assume any obligation to update such information to reflect later events or developments except as required by law.


'/>"/>
SOURCE QLT Inc.
Copyright©2008 PR Newswire.
All rights reserved


Related medicine news :

1. QLT announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System
2. Response Biomedical Announces Insider Participation in Current Financing
3. American National Announces Third Quarter 2008 Results
4. Digestive Care, Inc. Announces the Complete Submission of the NDA for PANCRECARB(R) (pancrelipase)
5. U.S. Preventive Medicine(R) Announces Major Development for The Prevention Plan(TM)
6. Haemonetics Announces Promotion of Brian Concannon to CEO Effective April 2009
7. HLTH Corporation Announces Commencement of Its Tender Offer
8. ReachMD XM 157 Announces Medical Information Feature on Treatment Options for Management of Hyponatremia
9. Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
10. UCSF Chancellor J. Michael Bishop Announces Plan To Step Down
11. USC Cancer Center Announces Contribution By Larry and Judy Freeman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: